vs

Side-by-side financial comparison of Delek US Holdings, Inc. (DK) and Labcorp (LH). Click either name above to swap in a different company.

Labcorp is the larger business by last-quarter revenue ($3.5B vs $2.4B, roughly 1.4× Delek US Holdings, Inc.). Labcorp runs the higher net margin — 4.7% vs 3.2%, a 1.5% gap on every dollar of revenue. On growth, Labcorp posted the faster year-over-year revenue change (5.6% vs 2.3%). Labcorp produced more free cash flow last quarter ($490.3M vs $382.8M). Over the past eight quarters, Labcorp's revenue compounded faster (5.2% CAGR vs -11.9%).

Delek US Holdings, Inc. is an oil refining, logistics and biofuels company founded in 2001 and headquartered in Brentwood, Tennessee.

Labcorp is a leading global life sciences and diagnostic testing firm that offers comprehensive clinical laboratory services, drug development support, and medical testing solutions for healthcare providers, pharmaceutical companies, and individual patients. It uses advanced scientific expertise and innovative technologies to deliver accurate, actionable health insights that support clinical decisions, accelerate new treatment development, and improve patient health outcomes globally.

DK vs LH — Head-to-Head

Bigger by revenue
LH
LH
1.4× larger
LH
$3.5B
$2.4B
DK
Growing faster (revenue YoY)
LH
LH
+3.3% gap
LH
5.6%
2.3%
DK
Higher net margin
LH
LH
1.5% more per $
LH
4.7%
3.2%
DK
More free cash flow
LH
LH
$107.5M more FCF
LH
$490.3M
$382.8M
DK
Faster 2-yr revenue CAGR
LH
LH
Annualised
LH
5.2%
-11.9%
DK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DK
DK
LH
LH
Revenue
$2.4B
$3.5B
Net Profit
$78.3M
$164.7M
Gross Margin
9.3%
28.2%
Operating Margin
6.8%
7.6%
Net Margin
3.2%
4.7%
Revenue YoY
2.3%
5.6%
Net Profit YoY
118.9%
14.9%
EPS (diluted)
$1.23
$1.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DK
DK
LH
LH
Q4 25
$2.4B
$3.5B
Q3 25
$2.9B
$3.6B
Q2 25
$2.8B
$3.5B
Q1 25
$2.6B
$3.3B
Q4 24
$2.4B
$3.3B
Q3 24
$3.0B
$3.3B
Q2 24
$3.3B
$3.2B
Q1 24
$3.1B
$3.2B
Net Profit
DK
DK
LH
LH
Q4 25
$78.3M
$164.7M
Q3 25
$178.0M
$261.1M
Q2 25
$-106.4M
$237.9M
Q1 25
$-172.7M
$212.8M
Q4 24
$-413.8M
$143.4M
Q3 24
$-76.8M
$169.3M
Q2 24
$-37.2M
$205.3M
Q1 24
$-32.6M
$228.0M
Gross Margin
DK
DK
LH
LH
Q4 25
9.3%
28.2%
Q3 25
13.8%
28.8%
Q2 25
1.9%
29.7%
Q1 25
-2.4%
28.3%
Q4 24
-5.7%
26.9%
Q3 24
-0.7%
27.6%
Q2 24
0.5%
28.8%
Q1 24
3.0%
28.2%
Operating Margin
DK
DK
LH
LH
Q4 25
6.8%
7.6%
Q3 25
10.2%
11.1%
Q2 25
-1.2%
11.2%
Q1 25
-4.8%
9.7%
Q4 24
-17.0%
6.5%
Q3 24
-4.0%
7.7%
Q2 24
0.1%
9.2%
Q1 24
0.9%
10.1%
Net Margin
DK
DK
LH
LH
Q4 25
3.2%
4.7%
Q3 25
6.2%
7.3%
Q2 25
-3.8%
6.7%
Q1 25
-6.5%
6.4%
Q4 24
-17.4%
4.3%
Q3 24
-2.5%
5.2%
Q2 24
-1.1%
6.4%
Q1 24
-1.0%
7.2%
EPS (diluted)
DK
DK
LH
LH
Q4 25
$1.23
$1.98
Q3 25
$2.93
$3.12
Q2 25
$-1.76
$2.84
Q1 25
$-2.78
$2.52
Q4 24
$-6.48
$1.72
Q3 24
$-1.20
$2.00
Q2 24
$-0.58
$2.43
Q1 24
$-0.51
$2.69

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DK
DK
LH
LH
Cash + ST InvestmentsLiquidity on hand
$625.8M
$532.3M
Total DebtLower is stronger
$3.2B
Stockholders' EquityBook value
$547.3M
$8.6B
Total Assets
$6.8B
$18.4B
Debt / EquityLower = less leverage
5.91×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DK
DK
LH
LH
Q4 25
$625.8M
$532.3M
Q3 25
$630.9M
$598.1M
Q2 25
$615.5M
$647.3M
Q1 25
$623.8M
$369.4M
Q4 24
$735.6M
$1.5B
Q3 24
$1.0B
$1.5B
Q2 24
$657.9M
$265.1M
Q1 24
$753.4M
$99.3M
Total Debt
DK
DK
LH
LH
Q4 25
$3.2B
Q3 25
$3.2B
Q2 25
$3.1B
Q1 25
$3.0B
Q4 24
$2.8B
Q3 24
$2.8B
Q2 24
$2.5B
Q1 24
$2.5B
Stockholders' Equity
DK
DK
LH
LH
Q4 25
$547.3M
$8.6B
Q3 25
$444.8M
$8.7B
Q2 25
$294.9M
$8.5B
Q1 25
$429.4M
$8.3B
Q4 24
$575.2M
$8.1B
Q3 24
$875.4M
$8.2B
Q2 24
$982.8M
$8.0B
Q1 24
$1.0B
$8.0B
Total Assets
DK
DK
LH
LH
Q4 25
$6.8B
$18.4B
Q3 25
$7.1B
$18.3B
Q2 25
$7.1B
$18.1B
Q1 25
$6.9B
$17.6B
Q4 24
$6.7B
$18.4B
Q3 24
$7.0B
$18.6B
Q2 24
$6.9B
$16.7B
Q1 24
$7.2B
$16.5B
Debt / Equity
DK
DK
LH
LH
Q4 25
5.91×
Q3 25
7.14×
Q2 25
10.51×
Q1 25
7.07×
Q4 24
4.81×
Q3 24
3.19×
Q2 24
2.50×
Q1 24
2.41×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DK
DK
LH
LH
Operating Cash FlowLast quarter
$502.8M
$614.2M
Free Cash FlowOCF − Capex
$382.8M
$490.3M
FCF MarginFCF / Revenue
15.8%
13.9%
Capex IntensityCapex / Revenue
4.9%
3.5%
Cash ConversionOCF / Net Profit
6.42×
3.73×
TTM Free Cash FlowTrailing 4 quarters
$6.3M
$1.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DK
DK
LH
LH
Q4 25
$502.8M
$614.2M
Q3 25
$44.0M
$387.2M
Q2 25
$51.4M
$620.6M
Q1 25
$-62.4M
$18.5M
Q4 24
$-163.5M
$777.2M
Q3 24
$-21.6M
$277.3M
Q2 24
$-48.4M
$561.1M
Q1 24
$166.7M
$-29.8M
Free Cash Flow
DK
DK
LH
LH
Q4 25
$382.8M
$490.3M
Q3 25
$-64.0M
$280.5M
Q2 25
$-114.4M
$542.7M
Q1 25
$-198.1M
$-107.5M
Q4 24
$-354.0M
$665.1M
Q3 24
$-140.6M
$161.5M
Q2 24
$-128.3M
$432.9M
Q1 24
$128.4M
$-163.6M
FCF Margin
DK
DK
LH
LH
Q4 25
15.8%
13.9%
Q3 25
-2.2%
7.9%
Q2 25
-4.1%
15.4%
Q1 25
-7.5%
-3.2%
Q4 24
-14.9%
20.0%
Q3 24
-4.6%
4.9%
Q2 24
-3.9%
13.4%
Q1 24
4.1%
-5.2%
Capex Intensity
DK
DK
LH
LH
Q4 25
4.9%
3.5%
Q3 25
3.7%
3.0%
Q2 25
6.0%
2.2%
Q1 25
5.1%
3.8%
Q4 24
8.0%
3.4%
Q3 24
3.9%
3.5%
Q2 24
2.4%
4.0%
Q1 24
1.2%
4.2%
Cash Conversion
DK
DK
LH
LH
Q4 25
6.42×
3.73×
Q3 25
0.25×
1.48×
Q2 25
2.61×
Q1 25
0.09×
Q4 24
5.42×
Q3 24
1.64×
Q2 24
2.73×
Q1 24
-0.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DK
DK

Refining$2.2B91%
Other$173.0M7%
Gravity Water Intermediate Holdings LLC Gravity$22.5M1%
Related Party$20.8M1%
Logistics$1.3M0%

LH
LH

Diagnostics$2.7B78%
Biopharma Laboratory Services$793.0M23%

Related Comparisons